A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer

被引：1
|
作者：
Lynce, Filipa
Yeh, Eren D.
Regan, Meredith M.
Qin, Lei
Bay, Camden P.
Krop, Ian
Harrison, Beth T.
Nakhlis, Faina
Bellon, Jennifer
Overmoyer, Beth
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-18
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer
    Overmoyer, B.
    Goel, S.
    Regan, M.
    Hirshfield-Bartek, J.
    Schlosnagel, E.
    Yeh, E.
    Qin, L.
    Bellon, J.
    Nakhlis, F.
    Jacene, H.
    Winer, E.
    CANCER RESEARCH, 2017, 77
  • [2] A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
    Yardley, Denise A.
    Shipley, Dianna
    Zubkus, John
    Wright, Gail L.
    Ward, Patrick J.
    Mani, Aruna
    Shastry, Mythili
    Finney, Lindsey
    DeBusk, Laura
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2019, 19 (01) : 1 - 9
  • [3] A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer
    Lim, Bora
    Song, Juhee
    Ibrahim, Nuhad K.
    Koenig, Kimberly B.
    Chavez-MacGregor, Mariana
    Ensor, Joe E., Jr.
    Gomez, Jill Schwartz
    Krishnamurthy, Savitri
    Caudle, Abigail S.
    Shaitelman, Simona F.
    Whitman, Gary J.
    Valero, Vicente
    ONCOLOGIST, 2021, 26 (02): : E230 - E240
  • [4] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 63 - 68
  • [5] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [6] Eribulin/Cyclophosphamide versus Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer: A Randomized Phase II Trial of the Sarah Cannon Research Institute
    Yardley, D. A.
    Hainsworth, J. D.
    Shastry, M.
    Finney, L.
    Burns, H. A.
    CANCER RESEARCH, 2012, 72
  • [7] A phase II randomized study with eribulin/cyclophosphamide (ErC) and docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in HER2-negative breast cancer-Final analysis of primary endpoint and correlative analysis results
    Yardley, D. A.
    Chandra, P.
    Hart, L.
    Wright, G. S.
    Ward, P.
    Mani, A.
    Shastry, M.
    Finney, L.
    Guo, S.
    DeBusk, L. M.
    Hainsworth, J. D.
    Burris, H. A., III
    CANCER RESEARCH, 2016, 76
  • [8] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
    Abraham, Jame
    Robidoux, Andr
    Tan, Antoinette R.
    Limentani, Steven
    Sturtz, Keren
    Shalaby, Ibrahim
    Alcorn, Hope
    Buyse, Marc E.
    Wolmark, Norman
    Jacobs, Samuel A.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (02) : 399 - 405
  • [9] Eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: A randomized phase II trial of the Sarah Cannon Research Institute
    Yardley, Denise
    Dyehouse, Karyn
    Mani, Aruna
    Calfa, Carmen
    Drosick, David
    Yost, Kathleen
    Shipley, Diana
    Quinn, Raven
    Young, Robyn
    Finney, Lindsey
    Earwood, Chris
    Shastry, Mythili
    Hainsworth, John
    CANCER RESEARCH, 2015, 75
  • [10] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
    Jame Abraham
    André Robidoux
    Antoinette R. Tan
    Steven Limentani
    Keren Sturtz
    Ibrahim Shalaby
    Hope Alcorn
    Marc E. Buyse
    Norman Wolmark
    Samuel A. Jacobs
    Breast Cancer Research and Treatment, 2015, 152 : 399 - 405
12345